Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Control group:Routine medicines and food
Experimental group:Taking Newgen beta-gluten probiotic composite powder
Sponsors
HwaMei Hospital, University of Chinese Academy of Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission. Criteria for diagnosis (meet all the following criteria): (1) With epidemiological history; (2) Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare; (3) Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2; 2. The person is treated with de-isolation and meets hospital discharge criteria according to the 'Diagnosis and treatment of novel coronavirus pneumonia (trial edition 5)'. However, the respiratory nucleic acid turned positive and there were changes in lung imaging; 3. Gastrointestinal anatomy and function allowed and use safely, without nausea, vomiting and other gastrointestinal symptoms.
Exclusion criteria
Exclusion criteria: 1. Gestational female patients; 2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage; 3. Patients with known psychiatric disorders; 4. Patients withdrawing from other clinical trial within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum albumin;siderophilin;prealbumin;lung CT scanning result; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of hospital stay;Length from the day of admission to the day returning to normal body temperature, from admission to two consecutive negative results of respiratory pathogenic nucleic acid test (sampling interval of at least 1 day), and from admission to the chest CT shows significant improvement.;height;weight;BMI;upper arm circumference;TSF;humoral immune indicators (IgA, IgG, IgM);Cellular immune indicators (total leukomonocyte count and T lymphocyte subsets (CD3,CD4);C-reactive protein;Inflammatory factors (including IL-2, IL-4, IL-6, IL-10, TNF-alpha, TFN-gama, etc.); | — |
Countries
China
Contacts
Public ContactHonghua Ye
HwaMei Hospital, University of Chinese Academy of Sciences
Outcome results
None listed